Indication is based on response rate in the indicated population.
No results available from randomized controlled trials in recurrent anaplastic astrocytoma demonstrating a clinical benefit from treatment, such as improvement in disease-related symptoms, delayed disease progression, or improved survival. Do not start the next cycle until the absolute neutrophil count and platelet count exceeds these levels. Drug can be continued until disease progresses. During the clinical trial, treatment could be continued for up to 2 years, although optimum duration is unknown. Drug absorption is affected by food, and temozolomide has been given under both fasting and nonfasting conditions.